Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02318329 · ClinicalTrials.gov registry record · Phase 1
Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors
A Phase 1 study of Gastric Cancer and Advanced Solid Tumors, sponsored by Five Prime Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 79
- Enrollment target
- 20
- Study locations
NCT02318329: Completed Phase 1 study of Gastric Cancer and Advanced Solid Tumors, sponsored by Five Prime Therapeutics.
NCT02318329 is a Phase 1 study of Gastric Cancer and Advanced Solid Tumors that has completed, run by Five Prime Therapeutics. The registered enrollment target is 79 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02318329, a Phase 1 study of Gastric Cancer and Advanced Solid Tumors, has completed, sponsored by Five Prime Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 79 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a three-part, open-label, safety, tolerability, and PK study of FPA144. Patients will be enrolled in Part 1 (A or B, dose escalation) or Part 2 (dose expansion) of the study, but not both.
Primary Outcome
Number of participants with grade 3 and grade 4 adverse events (AE) and clinical laboratory abnormalities defined as dose limiting toxicities (DLTs)
Conditions Studied
Interventions
- DRUG FPA144
Study Locations (20)
Other
- Seoul National University Bundang Hospital - Seongnam-si
- Seoul National University Hospital - Seoul
- Severance Hospital, Yonsei University - Seoul
- Samsung Medical Center - Seoul
- Gangnam Severance Hospital - Seoul
- Korea University Anam Hospital - Seoul
California
- City of Hope Comprehensive Cancer Center - Duarte
- Ronald Reagan UCLA Medical Center - Los Angeles
- UCSF Helen Diller Family Comprehensive Cancer Center, Mission Bay - San Francisco
- Innovative Cancer Research Institute - Whittier
Tennessee
- Sarah Cannon Research Institute, LLC - Nashville
- Vanderbilt University Medical Center - Nashville
Texas
- The University of Texas M.D. Anderson Cancer Center - Houston
- South Texas Accelerated Research Therapeutics, LLC - San Antonio
Illinois
- The University of Chicago Medical Center - Chicago
Massachusetts
- Dana-Farber Cancer Institute - Boston
Michigan
- Karmanos Cancer Institute - Detroit
New York
- Weill Cornell Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2014-11 |
| Est. Completion | 2019-06-30 |
| Phase | Phase 1 |
What the finished NCT02318329 record still lists
NCT02318329 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 79 participants, a relatively small participant target, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (75% lower).
The record links to 3 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 1 intervention - of which FPA144 is the first listed.
NCT02318329 names 20 study sites across 10 states, led by Other, California, Tennessee.
Frequently Asked Questions
What is clinical trial NCT02318329 about?
NCT02318329 is a clinical study titled "Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors". This is a three-part, open-label, safety, tolerability, and PK study of FPA144. Patients will be enrolled in Part 1 (A or B, dose escalation) or Part 2 (dose expansion) of the study, but not both.
What is the current status of trial NCT02318329?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 79 participants. The study started on 2014-11. Estimated completion is 2019-06-30.
What conditions does trial NCT02318329 study?
This clinical trial studies the following conditions: Gastric Cancer, Advanced Solid Tumors, Transitional Cell Carcinoma of the Bladder.
What interventions are being tested in trial NCT02318329?
The interventions under investigation include: FPA144 (DRUG).
Who is sponsoring clinical trial NCT02318329?
This trial is sponsored by Five Prime Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02318329 being conducted?
This trial has 20 study locations across California, Illinois, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02318329's enrollment target sits among peer trials
79 96th of 153 higher than 58 of 153 other Gastric Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05798897 · 79 participants · Phase 1
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- NCT06042439 · 79 participants · NA
AM vs PM Exercise Training
- NCT06223555 · 79 participants · NA
Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia